Alaunos Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $146.0K | $15.9M | $6.9M | — | — | — | $800.0K | $667.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $34.1M | $45.1M | $157.8M | $106.8M | $32.7M | $42.9M | $83.4M | $57.1M |
| SG&A Expense | $19.9M | $14.8M | $14.4M | $17.6M | $12.2M | $15.7M | $19.5M | $15.0M |
| Operating Income | $-53.9M | $-53.5M | $-165.3M | $-120.1M | $-43.5M | $-57.7M | $-102.2M | $-71.4M |
| Operating Margin | -36,921.9% | -336.4% | -2,409.4% | — | — | — | -12,771.1% | -10,704.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-53.1M | $-54.3M | $-165.3M | $-120.1M | $-31.8M | $-57.1M | $-96.1M | $-63.8M |
| Net Margin | -36,381.5% | -341.7% | -2,409.2% | — | — | — | -12,016.5% | -9,561.9% |
| EPS (Basic) | $0.96 | $-0.53 | $-1.32 | $-0.96 | $-0.31 | $-0.66 | $-1.22 | $-0.97 |
| EPS (Diluted) | $0.96 | $-0.53 | $-1.32 | $-0.96 | $-0.31 | $-0.66 | $-1.22 | $-0.97 |
| Shares Outstanding (Basic) | 143.5M | 136.9M | 130.4M | 131.7M | 104.5M | 100.2M | 83.2M | 69.2M |
| Shares Outstanding (Diluted) | 143.7M | 136.9M | 130.4M | 131.7M | 104.5M | 100.2M | 83.2M | 69.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |